DIRs, Clawbacks, & Opacity: CMS’ Drug Pricing Debacle | The PUTTcast

The unethical business practices by PBMs when it comes to our nation's seniors run the gamut from unreasonable fees and metrics to underhanded pricing models and what could easily be considered larceny against taxpayers. Join PUTTcast co-hosts Monique Whitney and Lauren Young, with special guests Tim Hamrick and Greg Reybold of APCI to discuss the results of their explosive 3Axis study, possible outcomes of the proposed CMS rule change, and why moving prescription drug plans to a NADAC pricing model is so important for lowering costs and increasing transparency.